Printer Friendly

FDA Accepts for Filing Eagle Pharmaceuticals ANDA for Vasopressin.

M2 PHARMA-April 18, 2018-FDA Accepts for Filing Eagle Pharmaceuticals ANDA for Vasopressin

(C)2018 M2 COMMUNICATIONS

- US-based specialty pharmaceutical company Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) has submitted, and the US Food and Drug Administration has accepted for filing, its abbreviated new drug application (ANDA) for vasopressin injection, 1ml, the company said.

This product is the generic version of Endo International plc's original Vasostrict formulation, which is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.

Vasostrict had approximately USD 400m in brand sales in 2017.

Eagle is focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle's strategy is to utilize the FDA's 505(b) (2) regulatory pathway.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 18, 2018
Words:148
Previous Article:Genentech Data Demonstrate Efficacy, Safety, and Benefits of Ocrevus in Relapsing and Primary Progressive MS.
Next Article:Data on Multiple Investigational Regimens for Treatment of NASH and Advanced Fibrosis Presented by Gilead at 2018 International Liver Congress.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |